All In Biotech

Investigational drug · Phase 3

JMT101

Not approved by FDA. In 7 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Local Advanced or Metastatic NSCLC, Recurrent or Metastatic Nasopharyngeal Cancer, Patients Who Have Experienced Treatment Failure at Least Second-line Chemotherapy.

Phase 3

Last checked: Nov 19, 2026Latest source record: Aug 27, 2025 (newest trial update)Source: ClinicalTrials.govMethods & limitations

Highest phase

Phase 3

Industry-sponsored trials

Phase 2 and 3 trials

7

7 still active

All registered trials

12

Any phase or sponsor naming "JMT101"

First trial start

2021

Nov 21, 2021

Sponsors

Lead sponsors of its Phase 2 and 3 trials.

All registered trials by phase

Every ClinicalTrials.gov drug study naming "JMT101", any sponsor or status.

Conditions studied

As listed on its trial records.

  • Local Advanced or Metastatic NSCLC
  • Recurrent or Metastatic Nasopharyngeal Cancer
  • Patients Who Have Experienced Treatment Failure at Least Second-line Chemotherapy
  • Metastatic Colorectal Cancer (mCRC)
  • Locally Advanced or Metastatic Non-squamous NSCLC
  • Harboring EGFR Sensitive Mutations NSCLC
  • Previously Untreated Systematically NSCLC
  • Squamous Cell Non-small Cell Lung Cancer
  • Harboring EGFR Common Mutation
  • Head and Neck Squamous Cell Carcinoma

Approved drugs for the same conditions: Non-small cell lung cancer · Small cell lung cancer · Colorectal cancer · Head and neck cancer · Oncology

Largest trials

Live from ClinicalTrials.gov: studies naming "JMT101" as an intervention, largest first.

All trials

Newest research

PubMed records naming it or its code names, newest first.

All 1 on PubMed

Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.